DSC Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

DSC Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-25,000	Closed	-$2.17M	–	31
2023 Q2	$2.17M	Buy	+25,000	New	+$2.35M	3.25%	9
2022 Q4	–	Sell	-40,000	Closed	-$3.39M	–	29
2022 Q3	$3.39M	Buy	+40,000	New	+$3.56M	3.49%	8
2022 Q1	–	Sell	-35,000	Closed	-$3.09M	–	133
2021 Q4	$3.09M	Buy	+35,000	New	+$2.89M	2.39%	9

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

DSC Advisors's BMRN Position: Q2 2024 in Review

DSC Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2024, closing a stake of 99,000 shares — an estimated $8.65M sold.

DSC Advisors first reported a position in BMRN in Q4 2021 and held it in 10 quarters. The position peaked at $9.64M in Q4 2023. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2024.

DSC Advisors reported no remaining BioMarin Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
DSC Advisors sold 99,000 BioMarin Pharmaceuticals shares in Q2 2024, an estimated $8.65M.
DSC Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2021 and held it in 10 quarters.
DSC Advisors's BioMarin Pharmaceuticals position peaked at $9.64M in Q4 2023.
558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2024.

Based on DSC Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.